ArticleFuture science OA2025
Predictors of frontline doublet or triplet regimen initiation in transplant-ineligible newly diagnosed multiple myeloma.
Article in Future science OA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo identify predictors for initiation of frontline doublet versus triplet therapy for transplant-ineligible newly diagnosed multiple myeloma. MATERIALS AND
methodsUsing Flatiron Health data, a random forest model was used to identify baseline predictors of frontline doublet or triplet use.
resultsThe random forest model had good predictive power, with 74% probability of successfully predicting the regimen received (doublets or triplets) for a given patient. Regression analyses found that patients treated with doublets were more likely to be older (age ≥80 versus <60 years: odds ratio [OR] = 0.15,
conclusionsWhile frontline triplet therapies have shown improved efficacy over doublets with tolerable safety, doublet use remains in older and frail patients, creating an opportunity to improve outcomes in this particular patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.